title: The role of Rixubis™ in the treatment of hemophilia B.
abstract: Hemophilia B is an inherited coagulopathy caused by the partial or complete deficiency of factor (F) IX. Factor replacement therapy, involving the intravenous infusion of plasma-derived or recombinant (r) FIX concentrate, is the cornerstone of treatment, used to control and prevent bleeding episodes. Although several plasma-derived FIX products are available, until recently, only a single rFIX concentrate was on the market. The aim of this paper is to review the pharmacokinetics, hemostatic efficacy, and safety of Rixubis™ (Baxter Healthcare Corporation, CA, USA), a newly licensed rFIX product.
authors.affiliation: Hemophilia & Thrombophilia Center, Rush University Medical Center, Chicago, IL USA.
authors.forename: Leonard A
authors.initials: LA
authors.lastname: Valentino
mesh_terms: D005164:Factor IX / Q000493:pharmacokinetics / Q000627:therapeutic use; D002836:Hemophilia B / Q000188:drug therapy*; D006490:Hemostatics / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D006490:Hemostatics; D011994:Recombinant Proteins; D005164:Factor IX